Large-Scale Protein Production with a Cell-Free System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Large-Scale Protein Production with a Cell-Free System


Equipment and Processing Report

Untitled Document

In vitro translation systems are based on the principle that protein synthesis does not require an intact cell. This principle led to the development of cell-free protein synthesis by Zubay in 1967. In cell-free production systems, translation is accomplished using a crude cell lysate that provides the necessary translational machinery, accessory enzymes, transfer RNA, and translation factors. The process also requires the addition of a nucleic-acid template, amino acids, and an energy source.

The primary limitation of cell-free, batch-mode reactions is their poor productivity, which results from the transience of the primary energy sources. Phosphoenolpyruvate (PEP), a phosphate energy source, is depleted rapidly, even in the absence of protein synthesis (1). In 1988, Alexander Spirin and colleagues at the Institute of Protein Research in Moscow created a continuous-flow, cell-free translation system to address the problem. This system continuously removes reaction byproducts and relies on a continuous supply of energy and substrates (2). Despite its improvement in yield, however, this system’s operational complexities make it extremely impractical.

Fig. 1 Yields of green fluorescent protein (GFP) resulting from batch synthesis (left column), the authors' system at high-throughput format (center column), and the authors' system at large-scale format (right column).
Figure 1: Yields of green fluorescent protein (GFP) resulting from batch synthesis (left column), the authors' system at high-throughput format (center column), and the authors' system at large-scale format (right column). Image is courtesy of the authors.

By replacing PEP with 3-phosphoglycerate as the primary energy source, productivity can be doubled. The latter energy source enables a steady supply of adenosine triphosphate (ATP), which stimulates protein synthesis (3). ATP production is sustained for a longer time in the presence of 3-phosphoglycerate than it is in the presence of PEP (4). Optimizing the reaction conditions in buffers by adding stabilizers for enzymes and improving the incubation conditions can improve productivity even further (5).

Several laboratories have tried to develop high-throughput, cell-free protein-synthesis systems (6–8). Swartz demonstrated that by using efficient and economical alternatives to PEP (e.g., pyruvate), mimicking Escherichia coli’s cytoplasmic environment, and stabilizing amino acids, it is possible to produce nearly one milligram of protein per milliliter of reaction using a batch format (9, 10).

The current authors sought to improve the productivity of protein synthesis by using a highly active cell-free extract from E. coli and by optimizing buffer conditions and shaking conditions. We also designed a new and simple device for high-throughput reactions. Using common laboratory equipment and materials, our system produces as much as 4 mg of green fluorescent protein (GFP) per milliliter of reaction in high-throughput and large-scale formats. This yield is equivalent to 4 g of GFP protein per liter of reaction (see Figure 1).

A high-throughput reaction requires a 48-well tissue-culture plate and 48 dialysis units. The authors performed cell-free reactions in quantities as large as 5 mL using a covered plastic container, a laboratory dialysis membrane, and clamps. Figure 1 demonstrates the similarity between the productivity of high-throughput (50-µL) and the large-scale (5-mL) operations. The system was about 10 times more efficient than conventional batch reactions with respect to the yield of GFP.

The technology could be useful to manufacture pharmaceutically important proteins on a much larger scale. A large-scale reaction device could be made by applying the techniques for scaling up standard dialysis reactions. Large-scale production of E. coli extract might result in a bottleneck, but it could be overcome by large-scale or continuous fermentation, centrifugation, and cell extraction.

References

  1. D.M. Kim and J.R. Swartz, Biotechnol. Bioeng. 66 (3), 180–188 (1999).
  2. A.S. Spirin et al., Science 242 (4882), 1162–1164 (1988).
  3. K. Sitaraman et al., J. Biotechnol. 110 (3), 257–263 (2004).
  4. J.W. Kuem et al., J. Biosci. Bioeng. 102 (2), 162–165 (2006).
  5. K. Sitaraman and D.K. Chatterjee, “Energetics in E. coli Based Batch Cell-Free Systems,” in Cell-Free Expression, Kudlicki et al., Eds. (Landes Bioscience, Austin, TX, 1st ed., 2007), pp. 42–52.
  6. Y. Endo and T. Sawasaki, J. Struct. Funct. Genomics 5 (1–2), 45–57 (2004).
  7. T. Sawasaki et al., FEBS Lett. 514 (1), 102–105 (2002).
  8. T. Kigawa et al., “Bacterial Cell-Free System for Highly Efficient Protein Synthesis,” in Cell-Free Protein Synthesis, A.S. Spirin and J.R. Swartz, Eds. (Wiley-VCH Verlag, Weinheim, Germany, 1st ed., 2008), pp. 83–97.
  9. M.C. Jewett and J.R. Swartz, Biotechnol. Bioeng. 86 (1), 19–26 (2004).
  10. N. Michel-Reydellet et al., Metab. Eng. 6 (3), 197–203 (2004).

Takashi Yabuki is a visiting scientist, and Deb K. Chatterjee is an associate director and senior principal scientist, both at SAIC-Frederick, the National Cancer Institute at Frederick, Frederick, MD 21702, yabukit@mail.nih.gov.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Equipment and Processing Report,
Click here